<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0011009'>Acute</z:hpo> suppression of dipeptidyl peptidase IV (DPP-IV) activity improves <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance in the <z:chebi fb="3" ids="16646">Zucker</z:chebi> fatty rat, a <z:e sem="disease" ids="C1519106" disease_type="Experimental Model of Disease" abbrv="">rodent model</z:e> of <z:hpo ids='HP_0000833'>impaired glucose tolerance</z:hpo>, through stabilization of glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi> (GLP)-1 </plain></SENT>
<SENT sid="1" pm="."><plain>This study describes the effects of a new and potent DPP-IV inhibitor, FE 999011, which is able to suppress plasma DPP-IV activity for 12 h after a single oral administration </plain></SENT>
<SENT sid="2" pm="."><plain>In the <z:chebi fb="3" ids="16646">Zucker</z:chebi> fatty rat, FE 999011 dose-dependently attenuated <z:chebi fb="105" ids="17234">glucose</z:chebi> excursion during an oral <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance test and increased GLP-1 (7-36) release in response to intraduodenal <z:chebi fb="105" ids="17234">glucose</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0011010'>Chronic</z:hpo> treatment with FE 999011 (10 mg/kg, twice a day for 7 days) <z:mp ids='MP_0005292'>improved glucose tolerance</z:mp>, as suggested by a decrease in the insulin-to-<z:chebi fb="105" ids="17234">glucose</z:chebi> ratio </plain></SENT>
<SENT sid="4" pm="."><plain>In the <z:chebi fb="3" ids="16646">Zucker</z:chebi> diabetic fatty (ZDF) rat, a <z:e sem="disease" ids="C1519106" disease_type="Experimental Model of Disease" abbrv="">rodent model</z:e> of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, <z:hpo ids='HP_0011010'>chronic</z:hpo> treatment with FE 999011 (10 mg/kg per os, once or twice a day) postponed the development of <z:mp ids='MP_0002055'>diabetes</z:mp>, with the twice-a-day treatment delaying the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> by 21 days </plain></SENT>
<SENT sid="5" pm="."><plain>In addition, treatment with FE 999011 stabilized food and water intake to <z:e sem="disease" ids="C0362046" disease_type="Disease or Syndrome" abbrv="">prediabetic</z:e> levels and reduced <z:hpo ids='HP_0002155'>hypertriglyceridemia</z:hpo> while preventing the rise in circulating free fatty acids </plain></SENT>
<SENT sid="6" pm="."><plain>At the end of treatment, basal plasma GLP-1 levels were increased, and pancreatic gene expression for GLP-1 receptor was significantly upregulated </plain></SENT>
<SENT sid="7" pm="."><plain>This study demonstrates that DPP-IV inhibitors such as FE 999011 could be of clinical value to delay the progression from <z:hpo ids='HP_0000833'>impaired glucose tolerance</z:hpo> to type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>